New Search

If you are not happy with the results below please do another search

23 search results for: INNA-051

21

ENA Respiratory Begins Phase I Study of COVID-19 Preventative Nasal Spray Designed to Stimulate Body’s Firstline Immune Defense in the Nose

First-in-class, fast-acting nasal spray designed to boost innate immunity against respiratory viruses including SARS-CoV-2 and its variants, influenza and the common cold at the first entry portal for most infections Company is recruiting study participants in the Sydney, Australia area Sydney, Australia, 13 July 2021 – ENA Respiratory, a biotechnology company developing a first-in-class nasal […]

22

ENA Respiratory Advances COVID-19 Preventative Therapy through AU$32 Million Funding Round

Round jointly led by Brandon Capital and Minderoo Foundation with co-investment from Uniseed will support the clinical development of INNA-051 Company appoints President and Chief Scientific Officer of the COPD Foundation and respiratory therapy expert Ruth Tal-Singer, Ph.D., to Board of Directors Sydney, Australia, 15 June – ENA Respiratory, a biotechnology company developing a first-in-class […]

23

ENA Respiratory announces an extension of its Series A and positive COVID-19 ferret challenge study results

A novel nasal treatment developed to boost the natural human immune system to fight common colds and flu, has proved remarkably successful in reducing COVID-19 viral replication test results, released today, reveal. The novel product, INNA-051, being developed by Australian biotech company, Ena Respiratory, reduced viral replication by up to 96 percent in a gold-standard […]